Szyman Catherine M.'s Form 4 filing
Edwards Lifesciences Corp (EW) · filed Nov 19, 2021
- Accession no.
- 0001225208-21-013981
- Filed
- Nov 19, 2021
- Trade date
- Nov 18, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.18M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Szyman Catherine M.CIK 0001438538 | Officer (CVP, Critical Care) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 | Common Stock | MOption exerciseAcquired | +10,000 | $21.76 | +$217,600 | 37,414.52 | Direct | |
| Nov 18, 2021 | Common Stock | SSaleDisposed | −1,253 | $118.87F2 | −$148,944.11 | 36,161.52 | Direct | |
| Nov 18, 2021 | Common Stock | SSaleDisposed | −2,390 | $116.98F3 | −$279,582.2 | 33,771.52 | Direct | |
| Nov 18, 2021 | Common Stock | SSaleDisposed | −6,357 | $117.88F4 | −$749,363.16 | 27,414.52 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 103,400 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $118.5900 to $118.8800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $116.4900 to $117.3600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $117.5790 to $118.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.